Articles tagged with Drug Therapy
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
The study investigates the effects of DPDT on human colon cancer HCT116 cells and non-tumorigenic MRC5 fibroblasts. The results show that DPDT preferentially targets HCT116 cells, inducing apoptosis and G2/M cell cycle arrest, likely through DNA topoisomerase I poisoning.
A randomized controlled trial found that time-restricted eating produced similar weight loss results to traditional calorie counting in a racially diverse population of adults with obesity. Participants who engaged in 8-hour time-restricted eating had improved insulin sensitivity compared to those in the control group.
The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.
A new molecular compound has been identified that can activate latent HIV-1 in cells, showing promise for HIV treatments. Researchers found that this compound, YSE028, can reactivate latently infected cells and induce cell death, potentially leading to a complete cure for HIV.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
A novel study found that honokiol promotes healing of rotator cuff injury and may be an effective treatment for humans. The study suggests that SIRT3 activation plays a protective role in alleviating aging-induced fibrocartilage degeneration and promoting rotator cuff healing.
Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
Scientists have discovered that dimethylfumarate can block blood clotting during infection, potentially treating life-threatening DIC and severe COVID-19. The mechanism involves blocking interferon production, which promotes tissue factor releases.
Researchers at IUPUI will lead two grants totaling $11.7 million to discover a drug treatment for hydrocephalus, a condition commonly associated with traumatic brain injury. The studies aim to test the effectiveness of treatments for three types of hydrocephalus and may lead to a new treatment option.
Fruquintinib has shown statistically significant improvement in overall survival and progression-free survival rates for patients with metastatic colorectal cancer. The median survival rate was 7.4 months, with a 34% reduction in death compared to the placebo group.
The Better Together trial partners with community organizations and sites to provide buprenorphine treatment, reducing distance for patients and offering peer support in familiar environments. Researchers aim to address barriers such as stigma, misunderstandings about addiction, and bias against certain treatments.
Researchers have developed a sonodynamic cancer immunotherapy based on semiconducting polymer nanoparticles that can be activated by ultrasound, effectively treating orthotopic pancreatic cancer in mouse models. The treatment induces immunogenic cell death and kills cancer cells without causing excessive immune responses.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
Scientists at RIKEN Center for Brain Science find that somatic mutations in six genes lead to intracranial aneurysms, which can be blocked with a drug. The study establishes the first non-surgical animal model of intracranial aneurysm and provides a potential new treatment option.
The use of psychedelics in mental health treatment is gaining traction, but concerns about patient safety and regulation need to be addressed. Psychedelic-assisted therapy shows promise in treating conditions like depression and PTSD, but more research is needed on dosages, settings, and guidelines.
A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.
A new study published in Journal of Leukocyte Biology found that age and sex differences contribute to increased inflammation in older female mice. The research team discovered that immune cells entering areas where they shouldn
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers from UTEP School of Pharmacy are exploring a new treatment for vascular dementia using the NIH grant to study the biological triggers behind the condition and test the effectiveness of candidate drug ZT-1a. The treatment aims to prevent cognitive impairments in dementia patients.
A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers at the National Human Genome Research Institute identified a potential treatment for disabling pansclerotic morphea, a severe inflammatory disease. They found that patients with the disorder have an overactive STAT4 protein and significantly improved symptoms with ruxolitinib, a JAK inhibitor.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
A study by Japanese researchers identifies the involvement of angiotensin II-AT1 and prostaglandin E2-EP1 systems in high-salt-induced hypertension and emotional/cognitive impairment, offering potential therapeutic targets for dementia prevention.
Two researchers will receive $1 million each for their five-year studies on new medication-based approaches to repair damaged aortas, as well as the effects of exercise on healing heart muscle and brain tissue after a heart attack or stroke. The American Heart Association's Merit Award supports innovative research with high impact.
Researchers developed a novel hybrid protein complex by binding lysozyme to copper for enhanced reactive oxygen species (ROS) removal. The CuST@lysozyme hybrid protein showed high SOD activity and stability in biological fluids, paving the way for its therapeutic applications.
Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.
Researchers at Weill Cornell Medicine have successfully converted human stomach stem cells into insulin-secreting cells, offering a promising approach to treating type 1 and severe type 2 diabetes. The transplants reversed disease signs in mouse models, suggesting good durability.
The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.
Researchers developed a drug treatment that inhibits YTHDF2, improving results of radiation therapy and preventing progression of distant metastasis. The treatment also prevents the "bad-scopal" effect, where radiation causes distant tumors to metastasize.
A recent study published in JAMA Psychiatry found that fewer boys aged 15-19 commit suicide in Swedish regions with higher bipolar diagnoses. The study, which analyzed registry data from 2008 to 2021, showed an inverse association between population-adjusted bipolar diagnoses and confirmed suicides among males.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
Researchers at Rensselaer Polytechnic Institute and Albany Medical College will use AI to develop a novel mesoscopic, multimodal preclinical imaging approach to test the hypothesis that drug distribution mediates tumor resistance. The goal is to improve targeted therapy for HER2-positive breast cancer.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A study of nearly 67,200 postmenopausal women found that the Fracture Risk Assessment Tool (FRAX) was inadequate for identifying osteoporotic fracture risk across racial/ethnic categories. However, the Osteoporosis Self-Assessment Tool (OST) was excellent for detecting osteoporosis within each category.
A Baylor team created a molecular classifier test to identify patients with HER2-positive breast cancer who may benefit from anti-HER2 therapy alone without chemotherapy. The test accurately predicts the most likely response of a tumor to specific treatment regimens, allowing for personalized de-escalation approaches.
A recent study found that COVID-19 infection can lead to increased infarct growth and ongoing tissue consumption even after successful reperfusion through angiography. This suggests a potentially aggressive clinical course for patients with COVID-19 and large-vessel occlusion acute ischemic stroke.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.
Researchers at Brigham and Women's Hospital have characterized the structure of amyloid-beta fibrils in the human brain, revealing their role in Alzheimer's disease progression. The study sheds light on how lecanemab, a US FDA-approved drug, exerts its protective effects by targeting these fibrils.
A study of 5302 patients found no significant difference in bleeding events between those temporarily discontinuing and maintaining antithrombotic therapy during image-guided breast biopsies. The findings support the safety of continuing antithrombotic therapy, but counsel patients on bruising risk.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
Researchers at McMaster University have found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA). A systematic review of 14 clinical trials and analysis of data from various databases revealed solriamfetol to be the best option.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
The IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases is the largest international scientific event devoted to musculoskeletal disorders. The congress presents new clinical advances and research on osteoporosis, osteoarthritis, sarcopenia, frailty, and rare skeletal disorders.
Researchers uncover a pathophysiological mechanism that initiates and sustains neuropathic pain in mice, identifying Tiam1 as a potential therapeutic target. Targeting spinal Tiam1 with antisense oligonucleotides alleviates neuropathic pain hypersensitivity, offering promise for treating chronic pain.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
A large study found no difference in cardiovascular outcomes between patients taking beta blockers and those who didn't, after a year of hospital discharge. The researchers suggest reevaluating the value of long-term beta blocker therapy in low-risk heart attack patients with normal functioning hearts.
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).